研究者詳細 - 髙橋　直人

研究等業績 - その他 - 髙橋　直人

分割表示 195 件中 61 - 80 件目／全件表示 >>

Adult-onset Still's Disease during Pregnancy Treated with Tocilizumab

Imaizumi C.

Internal Medicine ( Internal Medicine ) 61 ( 20 ) 3137 - 3140 2022年

A 28-year-old woman exhibited a spiking fever, arthritis, and liver disfunction when she was 22 weeks pregnant. She was diagnosed with adult-onset Still's disease (AOSD). As her condition was resistant to corticosteroid therapy, tocilizumab (TCZ) was selected. The TCZ treatment was effective, and she delivered a healthy child while receiving TCZ treatment. Cases in which AOSD first arises during pregnancy are rare, and there have been no reports of TCZ treatment for AOSD being initiated during pregnancy. Although the safety of TCZ treatment during pregnancy has not been established, it may be effective against severe AOSD that develops during pregnancy.

DOI PubMed CiNii Research

Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study

Yuda J.

Cancer Medicine ( Cancer Medicine ) 12 ( 3 ) 2990 - 2998 2022年

DOI

Bortezomib-EPOCH併用療法により長期寛解が得られたHIV陰性精巣原発形質芽球性リンパ腫

藤島崇嗣, 川端良成, 道下吉広, 北林淳, 高橋直人

臨床血液 ( 一般社団法人日本血液学会 ) 63 ( 10 ) 1386 - 1391 2022年

形質芽球性リンパ腫（PBL）は，HIV感染や免疫不全を背景に発症する稀なB細胞性リンパ腫である。今回，我々はHIV陰性精巣原発PBLに対し，bortezomib併用-EPOCH療法が著効し長期寛解が得られた症例を経験したので報告する。症例は86歳男性。免疫不全を伴う基礎疾患なし。急速に増大する右精巣腫瘍を認め，右高位精巣摘除術を施行した。摘除標本で形質細胞様異型リンパ球のびまん性増殖を認め，免疫組織化学染色で，CD38，CD138，CD56，λ，MUM1，EBER，MYC陽性であるが，CD20陰性，MIB1 index 90％であった。PET/CTで全身リンパ節腫脹を認めたが，骨髄および髄液浸潤はなく，PBL，臨床病期IIIE-A，IPI高中間リスクと診断した。髄注併用V-EPOCH療法を6コース施行し完全寛解が得られた。左精巣に予防的照射（計30 Gy）施行後，診断から2年半以上経過したが完全寛解を維持している。PBLは急速進行性で予後不良な疾患であるが，その稀少性から標準的治療は未確立である。精巣原発PBLに対し，髄注および局所照射を併用したV-EPOCH療法は，高齢者にも寛解と長期予後を期待できる有効な初期治療法の一つと考えられた。

DOI PubMed CiNii Research

Deep molecular response in patients with chronic phase chronic myeloid leukemia treated with the plasminogen activator inhibitor-1 inhibitor TM5614 combined with a tyrosine kinase inhibitor

Takahashi N.

Cancer Medicine ( Cancer Medicine ) 2022年

DOI

Development of an automatic multiplanar reconstruction processing method for head computed tomography

Sato M.

Journal of X-Ray Science and Technology ( Journal of X-Ray Science and Technology ) 30 ( 4 ) 777 - 788 2022年

DOI

Early Pulmonary Rehabilitation with Neuromuscular Electrical Stimulation in a Patient with Acute Exacerbation of Rheumatoid Arthritis-associated Interstitial Lung Disease: A Case Report

OKURA Kazuki, TAKAHASHI Yusuke, HASEGAWA Kakeru, HATAKEYAMA Kazutoshi, SAITO Kimio, IMAIZUMI Chihiro, KAGA Hajime, TAKAHASHI Naoto

Physical Therapy Research ( 一般社団法人日本理学療法学会連合 ) advpub ( 0 ) 2022年

Introduction: Early implementation of neuromuscular electrical stimulation (NMES) has been reported to prevent muscle atrophy and physical functional decline in patients requiring mechanical ventilation. However, its effect in patients with acute exacerbation of interstitial lung disease (ILD) remains unclear. We herein report our experience using the NMES combined with mobilization in a patient with an acute exacerbation of rheumatoid arthritis-associated ILD (RA-ILD) requiring mechanical ventilation. Case presentation: A 74-year-old man was admitted to the intensive care unit (ICU) and put on mechanical ventilation due to severe acute exacerbation of RA-ILD. Early mobilization and the NMES using a belt electrode skeletal muscle electrical stimulation system were started on day 7 of hospitalization (day 2 of ICU admission). The NMES duration was 20 min, performed once daily. The patient could perform mobility exercises on day 8 and could walk on day 16. We assessed his rectus femoris and quadriceps muscle thicknesses using ultrasound imaging, and found decreases of 4.5% and 8.4%, respectively, by day 14. On day 27, he could independently visit the lavatory, and the NMES was discontinued. He was instructed to start long-term oxygen therapy on day 49 and was discharged on day 63. His 6-minute walk distance was 308 m and his muscle thickness recovered to levels comparable to those at the initial evaluation at the time of discharge. Conclusion: Combining the NMES and mobilization started in the early phase and continued after ICU discharge was safe and effective in a patient with a severe acute exacerbation of RA-ILD.

DOI CiNii Research

Improving performance and self-efficacy of novice nurses using hybrid simulation-based mastery learning

Takashiki R.

Japan Journal of Nursing Science ( Japan Journal of Nursing Science ) 2022年

DOI

Ovarian Follicular Lymphoma Diagnosed due to Hydronephrosis

Noguchi Shinsuke, Kimura Yuiko, Shibano Sumire, Ariake Chika, Iwasawa Takuya, Oyama Noriaki, Sato Hirokazu, Enomoto Katsuhiko, Takahashi Naoto

Japanese Journal of Medicine ( 一般社団法人日本内科学会 ) advpub ( 0 ) 293 - 298 2022年

A 74-year-old woman presented with left lateral abdominal pain. Abdominal echography revealed left hydronephrosis and a pelvic mass. The patient underwent left adnexal resection of a suspected left ovarian tumor and was diagnosed with follicular lymphoma (FL) of clinical stage IIIA, grade 2. The patient was treated with rituximab-combined chemotherapy and achieved complete remission. The most common histological types of ovarian lymphoma are diffuse large B-cell lymphoma and Burkitt lymphoma, with FL being an extremely rare variant. We herein report a case of ovarian FL diagnosed as hydronephrosis.

DOI PubMed CiNii Research

Clinical outcomes of second-generation tyrosine kinase inhibitors versus imatinib in older patients with CML

Ono T.

Cancer Science ( Cancer Science ) 114 ( 3 ) 995 - 1006 2022年

DOI

Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome-positive acute lymphoblastic leukaemia patients

Fukushi Y.

British Journal of Clinical Pharmacology ( British Journal of Clinical Pharmacology ) 89 ( 5 ) 1695 - 1700 2022年

The effects of polymorphisms of ABCB1 and ABCG2 on the dose-adjusted plasma trough concentrations and cerebrospinal fluid (CSF)-to-plasma ratios of ponatinib were evaluated. Blood (C4 ) and CSF (CSF4 ) concentrations at 4 h after administration were determined. The median (95% confidence interval) CSF4 -to-C4 ratio of ponatinib in subjects homozygous for ABCB1 variants 1236T/T, 2677T/T + T/A or 3435T/T were significantly higher than that in a group of subjects with other genotypes (P = .026, .012 and .015, respectively). The median (95% confidence interval) CSF4 -to-C4 ratio of ponatinib in 4 patients with the combination of ABCB1 variants 1236T/T-2677T/T + T/A-3435T/T was 2.62% (1.42-3.42%); this ratio was significantly higher than that in subjects with other genotypes (1.08% [0.89-1.47%]; P = .006). The brain distribution of ponatinib was affected by ABCB1 polymorphisms and therefore seems to be modulated by P-glycoprotein at the blood-brain and blood-CSF barriers.

DOI PubMed

Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy

Abumiya M.

Scientific Reports ( Scientific Reports ) 11 ( 1 ) 6362 - 6362 2021年12月

The purpose of this study was to investigate the effects of SLC22A2 808G>T polymorphism and trough concentrations (C0) of bosutinib on serum creatinine in 28 patients taking bosutinib. At 1, 3, 6, 12, 24, and 36 months after administration, analysis of bosutinib C0 and creatinine was performed at the same time of day. Significant correlations were observed between bosutinib C0 and the change rate of serum creatinine or the estimated glomerular filtration rate (eGFR; r = 0.328, P < 0.001 and r = - 0.315, P < 0.001, respectively). These correlations were particularly high in patients having the SLC22A2 808G/G genotype (r = 0.345 and r = - 0.329, respectively); however, in patients having the 808T allele, there were no significant differences. In multivariate analyses, the SLC22A2 808G/G genotype, patient age, bosutinib C0 and second-line or later bosutinib were independent factors influencing the change rate of creatinine. Bosutinib elevated serum creatinine through organic cation transporter 2 (OCT2). We observed a 20% increase in serum creatinine with a median bosutinib C0 of 63.4-73.2 ng/mL. Periodic measurement of serum creatinine after bosutinib therapy is necessary to avoid progression to severe renal dysfunction from simple elevation of creatinine mediated by OCT2 following bosutinib treatment.

DOI PubMed

Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia

Ochi Y.

Nature Communications ( Nature Communications ) 12 ( 1 ) 2021年12月

DOI

Regulatory t cell as a biomarker of treatment-free remission in patients with chronic myeloid leukemia

Fujioka Y.

Cancers ( Cancers ) 13 ( 23 ) 2021年12月

DOI

ANCA関連腎炎の臨床病理学的重症度と好中球細胞外トラップ

齋藤雅也, 齋藤綾乃, 阿部史人, 今泉ちひろ, 加賀一, 奈良瑞穂, 高橋直人

秋田腎不全研究会誌 ( 秋田腎不全研究会 ) 24 19 - 27 2021年11月

Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL

Kawano N.

International Journal of Hematology ( International Journal of Hematology ) 114 ( 4 ) 509 - 516 2021年10月

Although tyrosine kinase inhibitors (TKIs) play a crucial role in the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL), intolerance and resistance to TKIs have been serious problems. Due to a lack of research, the importance of the pharmacokinetics (PK) of TKIs is currently unclear. We examined the PK of the third-generation TKI ponatinib to monitor side effects and efficacy during treatments for one patient with CML-chronic phase (CP-CML) and two who received allogeneic hematopoietic stem cell transplantation (allo-HSCT), one for CML-blastic crisis (BC-CML) and one for Ph + ALL. The patient with CP-CML was intolerant to multiple TKIs (dasatinib, nilotinib, imatinib, and bosutinib) and thus was switched to ponatinib (15 mg/day). The patients who received allo-HSCT for BC-CML and Ph + ALL received ponatinib (15 mg/day) as maintenance therapy. Notably, serial evaluation of the PK of ponatinib showed that the median trough values (ng/ml) were 17.2 (12.2–34.5), 33.1 (21.2–40.3) and 27.7 (13.6–29.9) in patients 1, 2, and 3, respectively. These values were around the target concentration (23 ng/ml). All patients are maintaining complete remission without side effects. In conclusion, serial evaluation of PK of ponatinib may yield meaningful information about its safety and efficacy.

DOI PubMed

Multiple myeloma with t(11;14)-associated immature phenotype has lower CD38 expression and higher BCL2 dependence

Kitadate A.

Cancer Science ( Cancer Science ) 112 ( 9 ) 3645 - 3654 2021年09月

DOI

IGL/MYC再構成を有し、かつCD138の発現を伴うB細胞性リンパ芽球性白血病(Precursor B-lymphoblastic leukemia with IGL/MYC rearrangement and CD138 expression)

倉橋保奈実, 山下鷹也, 北舘明宏, 道下吉広, 川端良成, 北林淳, 松本奈津美, 齋藤雅也, 小林敬宏, 藤島直仁, 亀岡吉弘, 高橋直人

日本血液学会学術集会 ( (一社)日本血液学会 ) 83回 OS3 - 3 2021年09月

MYCの転座相手が非IgHと考えられるdouble hit lymphoma

安田拓人, 亀岡吉弘, 橋本眞子, 藤岡優樹, 斎藤雅也, 鵜生川久美, 高橋直人

臨床血液 ( (一社)日本血液学会-東京事務局 ) 62 ( 9 ) 1417 - 1418 2021年09月

慢性リンパ性白血病に合併したmonoclonal immunotactoid glomerulopathy